Melvin Spigelman
Director/Board Member en AN2 THERAPEUTICS, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Melvin K.
Spigelman is currently the President, Chief Executive Officer & Director at Global Alliance for TB Drug Development.
He is also a Director at Tres Cantos Open Lab Foundation, a Director at AN2 Therapeutics, Inc., and a Venture Partner at Wellington Partners GmbH.
Previously, Dr. Spigelman served as the Chairman of Synergy Pharmaceuticals LLC from 2018 to 2019.
He was an Independent Director at The Medicines Co. from 2005 to 2018.
He also held the position of Vice President-Global Clinical Centers at Abbott India Ltd.
and Knoll Pharmaceutical Co. from 2000 to 2001.
Additionally, he was the President of Hudson-Douglas Ltd.
in 2003.
Dr. Spigelman received his undergraduate degree from Brown University and his doctorate from Icahn School of Medicine at Mount Sinai.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
-.--% | 07/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Melvin Spigelman
| Empresas | Cargo | Inicio |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Director/Board Member | 01/02/2022 |
Global Alliance for TB Drug Development
 Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Chief Executive Officer | 01/01/2009 |
Wellington Partners GmbH
 Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Private Equity Investor | 01/01/2005 |
Tres Cantos Open Lab Foundation
 Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Tres Cantos Open Lab Foundation provides research facilities for charity. The non-profit company is based in Guildford, UK. | Director/Board Member | - |
Antiguos cargos conocidos de Melvin Spigelman.
| Empresas | Cargo | Fin |
|---|---|---|
| SYNERGY PHARMACEUTICALS INC | Chairman | 01/05/2019 |
| THE MEDICINES COMPANY | Director/Board Member | 01/01/2018 |
| Hudson-Douglas Ltd. | President | 01/06/2003 |
| ABBOTT INDIA LIMITED | Chief Tech/Sci/R&D Officer | 01/01/2000 |
| Knoll Pharmaceutical Co. | Chief Tech/Sci/R&D Officer | 01/01/2000 |
Formación de Melvin Spigelman.
| Brown University | Undergraduate Degree |
| Icahn School of Medicine at Mount Sinai | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ABBOTT INDIA LIMITED | Health Technology |
| AN2 THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 7 |
|---|---|
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
Global Alliance for TB Drug Development
Global Alliance for TB Drug Development Pharmaceuticals: GenericHealth Technology Global Alliance for TB Drug Development operates as a not-for-profit organization dedicated to the discovery and development of tuberculosis drugs. It builds partnerships between the public, private, academic, and philanthropic sectors to drive the development of new products for underserved markets. The company was founded in February 2000 and is headquartered in New York , NY. | Health Technology |
Wellington Partners GmbH
Wellington Partners GmbH Investment ManagersFinance Wellington Partners GmbH (Wellington Partners) is an independent venture capital firm founded in 1991 by Rolf Christof Dienst. The firm is headquartered in Munich, with offices in Zurich, London, and Palo Alto. | Finance |
| Knoll Pharmaceutical Co. | |
| Hudson-Douglas Ltd. | |
Tres Cantos Open Lab Foundation
Tres Cantos Open Lab Foundation Miscellaneous Commercial ServicesCommercial Services Tres Cantos Open Lab Foundation provides research facilities for charity. The non-profit company is based in Guildford, UK. | Commercial Services |
Synergy Pharmaceuticals LLC
 Synergy Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Synergy Pharmaceuticals LLC engages on the development and commercialization of novel gastrointestinal therapies. Its commercial product, plecanatide, is marketed under the trademark name TRULANCE, which seeks to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. The company was founded by Kunwar Shailubhai and is headquartered in New York, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Melvin Spigelman
